Abstract
Radical prostatectomy (RP) remains the standard treatment for men with clinically localized prostate cancer, despite the range of alternative treatment modalities. Even with significant advances in surgical technique and superb results for cancer control and preservation of urinary function, erectile dysfunction (ED) following RP is a common complication. This is mainly attributed to temporary cavernous nerve damage (neuropraxia) resulting in penile hypoxia, smooth muscle apoptosis, fibrosis and veno-occlusive dysfunction. One of the most promising new approaches is the concept of early penile rehabilitation, which is thought to prevent ED after RP by countering post-RP pathophysiological changes during the period of neural recovery. Various treatments, such as vacuum constriction devices, intraurethral and intracorporal alprostadil, and phosphodiesterase type 5 (PDE5) inhibitors, might serve to facilitate recovery of erectile function. PDE5 inhibitors are considered as the first-line treatment for early penile rehabilitation, with superior erectile function outcomes compared to placebo. Definitive conclusions regarding the success of penile rehabilitation cannot be drawn at this time because of differences in study design, data acquisition, and definitions of potency. Continued prospective, rigorous study is needed to develop and bring forward this important field and to establish the best evidence basis for counseling and treating patients suffering from ED after RP.
Key Points
-
Despite advances in surgical technique, erectile dysfunction (ED) remains one of the major complications following radical prostatectomy (RP) affecting health-related quality of life
-
Post-RP ED is considered a consequence of postoperative neuropraxia resulting in penile hypoxia, smooth muscle apoptosis, fibrosis and veno-occlusive dysfunction
-
One promising approach to prevent post-RP ED is the concept of early penile rehabilitation with various treatment options
-
PDE5 inhibitors are currently considered as the first-line treatment for early penile rehabilitation
-
The majority of published data are limited by discrepancies in study design, data acquisition, and inconsistencies in defining adequate erectile function
-
Definite conclusions regarding the success of penile rehabilitation cannot be drawn at this time
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer V.2.2009 http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
Bill-Axelson, A. et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N. Engl. J. Med. 352, 1977–1984 (2005).
Nielsen, M. E., Schaeffer, E. M., Marschke, P. & Walsh, P. C. High anterior release of the levator fascia improves sexual function following open radical retropubic prostatectomy. J. Urol. 180, 2557–2564 (2008).
Menon, M. et al. Vattikuti Institute prostatectomy: contemporary technique and analysis of results. Eur. Urol. 51, 648–657 (2007).
Walsh, P. C. & Donker, P. J. Impotence following radical prostatectomy: insight into etiology and prevention. J. Urol. 128, 492–497 (1982).
Walsh, P. C. et al. Preservation of sexual function in men during radical pelvic surgery. Md Med. J. 39, 389–393 (1990).
Takenaka, A., Murakami, G., Matsubara, A., Han, S. H. & Fujisawa, M. Variation in course of cavernous nerve with special reference to details of topographic relationships near prostatic apex: histologic study using male cadavers. Urology 65, 136–142 (2005).
Savera, A. T. et al. Robotic radical prostatectomy with the “Veil of Aphrodite” technique: histologic evidence of enhanced nerve sparing. Eur. Urol. 49, 1065–1073 (2006).
Young, H. H. VIII. Conservative perineal prostatectomy: the results of two years' experience and report of seventy-five cases. Ann. Surg. 41, 549–557 (1905).
Walsh, P. C. The discovery of the cavernous nerves and development of nerve sparing radical retropubic prostatectomy. J. Urol. 177, 1632–1635 (2007).
Bishoff, J. T. et al. Incidence of fecal and urinary incontinence following radical perineal and retropubic prostatectomy in a national population. J. Urol. 160, 454–458 (1998).
Eastham, J. A. & Scardino, P. T. in Campbell–Walsh Urology (eds. Wein, A. J., Kavoussi, L. R., Novick, A.-W., Partin, A. W. & Peters, C. A.) 2934–2938 (Saunders, Philadelphia, PA, 2007).
Zorn, K. C. et al. Da Vinci robot error and failure rates: single institution experience on a single three-arm robot unit of more than 700 consecutive robot-assisted laparoscopic radical prostatectomies. J. Endourol. 21, 1341–1344 (2007).
Guillonneau, B., Cathelineau, X., Barret, E., Rozet, F. & Vallancien, G. Laparoscopic radical prostatectomy. Preliminary evaluation after 28 interventions [French]. Presse Med. 27, 1570–1574 (1998).
Rassweiler, J., Hruza, M., Teber, D. & Su, L. M. Laparoscopic and robotic assisted radical prostatectomy--critical analysis of the results. Eur. Urol. 49, 612–624 (2006).
Binder, J. & Kramer, W. Robotically-assisted laparoscopic radical prostatectomy. BJU Int. 87, 408–410 (2001).
Berryhill, R. Jr et al. Robotic prostatectomy: a review of outcomes compared with laparoscopic and open approaches. Urology 72, 15–23 (2008).
Box, G. N. & Ahlering, T. E. Robotic radical prostatectomy: long-term outcomes. Curr. Opin. Urol. 18, 173–179 (2008).
Fowler, F. J. Jr et al. Patient-reported complications and follow-up treatment after radical prostatectomy. The National Medicare Experience: 1988–1990 (updated June 1993). Urology 42, 622–629 (1993).
Kundu, S. D. et al. Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies. J. Urol. 172, 2227–2231 (2004).
Walsh, P. C., Marschke, P., Ricker, D. & Burnett, A. L. Patient-reported urinary continence and sexual function after anatomic radical prostatectomy. Urology 55, 58–61 (2000).
Litwin, M. S. et al. Sexual function and bother after radical prostatectomy or radiation for prostate cancer: multivariate quality-of-life analysis from CaPSURE. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology 54, 503–508 (1999).
Rozet, F. et al. Extraperitoneal laparoscopic radical prostatectomy: a prospective evaluation of 600 cases. J. Urol. 174, 908–911 (2005).
Penson, D. F. et al. 5-year urinary and sexual outcomes after radical prostatectomy: results from the Prostate Cancer Outcomes Study. J. Urol. 179 (5 Suppl.), S40–S44 (2008).
Burnett, A. L. et al. Erectile function outcome reporting after clinically localized prostate cancer treatment. J. Urol. 178, 597–601 (2007).
Ball, A. J. et al. Prospective longitudinal comparative study of early health-related quality-of-life outcomes in patients undergoing surgical treatment for localized prostate cancer: a short-term evaluation of five approaches from a single institution. J. Endourol. 20, 723–731 (2006).
Anastasiadis, A. G. et al. Radical retropubic versus laparoscopic prostatectomy: a prospective comparison of functional outcome. Urology 62, 292–297 (2003).
Rabbani, F., Stapleton, A. M., Kattan, M. W., Wheeler, T. M. & Scardino, P. T. Factors predicting recovery of erections after radical prostatectomy. J. Urol. 164, 1929–1934 (2000).
Mulhall, J. P. Defining and reporting erectile function outcomes after radical prostatectomy: challenges and misconceptions. J. Urol. 181, 462–471 (2009).
Kendirci, M., Bejma, J. & Hellstrom, W. J. Update on erectile dysfunction in prostate cancer patients. Curr. Opin. Urol. 16, 186–195 (2006).
Hatzimouratidis, K. et al. Phosphodiesterase type 5 inhibitors in oostprostatectomy erectile dysfunction: a critical analysis of the basic science rationale and clinical application. Eur. Urol. 55, 334–347 (2009).
Klein, L. T. et al. Apoptosis in the rat penis after penile denervation. J. Urol. 158, 626–630 (1997).
Moreland, R. B. Is there a role of hypoxemia in penile fibrosis: a viewpoint presented to the Society for the Study of Impotence. Int. J. Impot. Res. 10, 113–120 (1998).
Leungwattanakij, S. et al. Cavernous neurotomy causes hypoxia and fibrosis in rat corpus cavernosum. J. Androl. 24, 239–245 (2003).
Mullerad, M., Donohue, J. F., Li, P. S., Scardino, P. T. & Mulhall, J. P. Functional sequelae of cavernous nerve injury in the rat: is there model dependency. J. Sex. Med. 3, 77–83 (2006).
Granchi, S. et al. Expression and regulation of endothelin-1 and its receptors in human penile smooth muscle cells. Mol. Hum. Reprod. 8, 1053–1064 (2002).
Montorsi, F. et al. Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: results of a prospective, randomized trial. J. Urol. 158, 1408–1410 (1997).
Mulhall, J. P. et al. Erectile dysfunction after radical prostatectomy: hemodynamic profiles and their correlation with the recovery of erectile function. J. Urol. 167, 1371–1375 (2002).
Kovanecz, I. et al. Chronic daily tadalafil prevents the corporal fibrosis and veno-occlusive dysfunction that occurs after cavernosal nerve resection. BJU Int. 101, 203–210 (2008).
Kovanecz, I. et al. Long-term continuous sildenafil treatment ameliorates corporal veno-occlusive dysfunction (CVOD) induced by cavernosal nerve resection in rats. Int. J. Impot. Res. 20, 202–212 (2008).
Ferrini, M. G. et al. Vardenafil prevents fibrosis and loss of corporal smooth muscle that occurs after bilateral cavernosal nerve resection in the rat. Urology 68, 429–435 (2006).
Sezen, S. F., Lagoda, G. & Burnett, A. L. Role of immunophilins in recovery of erectile function after cavernous nerve injury. J. Sex. Med. 6 (Suppl. 3), 340–346 (2009).
Rogers, C. G., Trock, B. P. & Walsh, P. C. Preservation of accessory pudendal arteries during radical retropubic prostatectomy: surgical technique and results. Urology 64, 148–151 (2004).
McCullough, A., Woo, K., Telegrafi, S. & Lepor, H. Is sildenafil failure in men after radical retropubic prostatectomy (RRP) due to arterial disease? Penile duplex Doppler findings in 174 men after RRP. Int. J. Impot. Res. 14, 462–465 (2002).
Walsh, P. C., Lepor, H. & Eggleston, J. C. Radical prostatectomy with preservation of sexual function: anatomical and pathological considerations. Prostate 4, 473–485 (1983).
Walsh, P. C. in Campbell-Walsh Urology (eds. Wein, J., Kavoussi, L. R., Novick, A. C., Partin, A. W. & Peters, C. A.) 2956–2978 (WB Saunders, Philadelphia, 2006).
Dubbelman, Y. D., Dohle, G. R. & Schroder, F. H. Sexual function before and after radical retropubic prostatectomy: A systematic review of prognostic indicators for a successful outcome. Eur. Urol. 50, 711–718 (2006).
Quinlan, D. M., Nelson, R. J. & Walsh, P. C. Cavernous nerve grafts restore erectile function in denervated rats. J. Urol. 145, 380–383 (1991).
Walsh, P. C. Nerve grafts are rarely necessary and are unlikely to improve sexual function in men undergoing anatomic radical prostatectomy. Urology 57, 1020–1024 (2001).
Kim, E. D. et al. Interposition of sural nerve restores function of cavernous nerves resected during radical prostatectomy. J. Urol. 161, 188–192 (1999).
Kim, E. D. et al. Bilateral nerve grafting during radical retropubic prostatectomy: extended follow-up. Urology 58, 983–987 (2001).
Zorn, K. C. et al. Long-term functional and oncological outcomes of patients undergoing sural nerve interposition grafting during robot-assisted laparoscopic radical prostatectomy. J. Endourol. 22, 1005–1012 (2008).
Porpiglia, F. et al. Is laparoscopic unilateral sural nerve grafting during radical prostatectomy effective in retaining sexual potency? BJU Int. 95, 1267–1271 (2005).
Mikhail, A. A. et al. Sural nerve grafting in robotic laparoscopic radical prostatectomy: interim report. J. Endourol. 21, 1547–1551 (2007).
Quinlan, D. M., Epstein, J. I., Carter, B. S. & Walsh, P. C. Sexual function following radical prostatectomy: influence of preservation of neurovascular bundles. J. Urol. 145, 998–1002 (1991).
Davis, J. W. et al. Randomized phase II trial evaluation of erectile function after attempted unilateral cavernous nerve-sparing retropubic radical prostatectomy with versus without unilateral sural nerve grafting for clinically localized prostate cancer. Eur. Urol. 55, 1135–1144 (2009).
Haber, G. P., Aron, M., Ukimura, O. & Gill, I. S. Energy-free nerve-sparing laparoscopic radical prostatectomy: the bulldog technique. BJU Int. 102, 1766–1769 (2008).
Guru, K. A., Perlmutter, A. E., Butt, Z. M. & Peabody, J. O. Hydrodissection for preservation of neurovascular bundle during robot-assisted radical prostatectomy. Can. J. Urol. 15, 4000–4003 (2008).
Finley, D. S., Osann, K., Skarecky, D. & Ahlering, T. E. Hypothermic nerve-sparing radical prostatectomy: rationale, feasibility, and effect on early continence. Urology 73, 691–696 (2009).
Boyette, L. B. et al. Fiberoptic imaging of cavernous nerves in vivo. J. Urol. 178, 2694–2700 (2007).
Briganti, A. & Montorsi, F. Penile rehabilitation after radical prostatectomy. Nat. Clin. Pract. Urol. 3, 400–401 (2006).
Mulhall, J. P. Penile rehabilitation following radical prostatectomy. Curr. Opin. Urol. 18, 613–620 (2008).
Cookson, M. S. & Nadig, P. W. Long-term results with vacuum constriction device. J. Urol. 149, 290–294 (1993).
Hall, M. C. Management of erectile dysfunction after radical prostatectomy. Semin. Urol. Oncol. 13, 215–223 (1995).
Zippe, C. D. et al. Management of erectile dysfunction following radical prostatectomy. Curr. Urol. Rep. 2, 495–503 (2001).
Kohler, T. S. et al. A pilot study on the early use of the vacuum erection device after radical retropubic prostatectomy. BJU Int. 100, 858–862 (2007).
Raina, R. et al. Early use of vacuum constriction device following radical prostatectomy facilitates early sexual activity and potentially earlier return of erectile function. Int. J. Impot. Res. 18, 77–81 (2006).
Raina, R., Agarwal, A., Allamaneni, S. S., Lakin, M. M. & Zippe, C. D. Sildenafil citrate and vacuum constriction device combination enhances sexual satisfaction in erectile dysfunction after radical prostatectomy. Urology 65, 360–364 (2005).
Virag, R. Intracavernous injection of papaverine for erectile failure. Lancet 2, 938 (1982).
Urciuoli, R., Cantisani, T. A., CarliniI, M., Giuglietti, M. & Botti, F. M. Prostaglandin E1 for treatment of erectile dysfunction. Cochrane Database of Systematic Reviews 2004, Issue 2. Art. No.: CD001784. doi:10.1002/14651858.CD001784.pub2.
Nandipati, K., Raina, R., Agarwal, A. & Zippe, C. D. Early combination therapy: intracavernosal injections and sildenafil following radical prostatectomy increases sexual activity and the return of natural erections. Int. J. Impot. Res. 18, 446–451 (2006).
Mydlo, J. H., Viterbo, R. & Crispen, P. Use of combined intracorporal injection and a phosphodiesterase-5 inhibitor therapy for men with a suboptimal response to sildenafil and/or vardenafil monotherapy after radical retropubic prostatectomy. BJU Int. 95, 843–846 (2005).
Padma-Nathan, H. et al. Hemodynamic effects of intraurethral alprostadil: the mediated urethal system for erection (MUSE). J. Urol. 151, 345 (1994).
Costabile, R. A. et al. Efficacy and safety of transurethral alprostadil in patients with erectile dysfunction following radical prostatectomy. J. Urol. 160, 1325–1328 (1998).
Raina, R., Pahlajani, G., Agarwal, A. & Zippe, C. D. The early use of transurethral alprostadil after radical prostatectomy potentially facilitates an earlier return of erectile function and successful sexual activity. BJU Int. 100, 1317–1321 (2007).
Montorsi, F., Briganti, A., Salonia, A., Rigatti, P. & Burnett, A. L. Current and future strategies for preventing and managing erectile dysfunction following radical prostatectomy. Eur. Urol. 45, 123–133 (2004).
Doggrell, S. Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction? Int. J. Impot. Res. 19, 281–295 (2007).
Padma-Nathan, H. et al. Randomized, double-blind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy. Int. J. Impot. Res. 20, 479–486 (2008).
Schwartz, E. J., Wong, P. & Graydon, R. J. Sildenafil preserves intracorporeal smooth muscle after radical retropubic prostatectomy. J. Urol. 171, 771–774 (2004).
Montorsi, F. et al. Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: a randomized, double-blind, placebo controlled trial. J. Urol. 172, 1036–1041 (2004).
Nehra, A., Grantmyre, J., Nadel, A., Thibonnier, M. & Brock, G. Vardenafil improved patient satisfaction with erectile hardness, orgasmic function and sexual experience in men with erectile dysfunction following nerve sparing radical prostatectomy. J. Urol. 173, 2067–2071 (2005).
Montorsi, F. et al. Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. Eur. Urol. 54, 924–931 (2008).
Novara, G. & Ficarra, V. Re: Francesco Montorsi, Gerald Brock, Jay Lee. et al. Effect of Nightly versus On-Demand Vardenafil on Recovery of Erectile Function in Men Following Bilateral Nerve-Sparing Radical Prostatectomy. Eur. Urol. 55, e95–e96 (2009).
Martin-Morales, A., Haro, J. M., Beardsworth, A., Bertsch, J. & Kontodimas, S. Therapeutic effectiveness and patient satisfaction after 6 months of treatment with tadalafil, sildenafil, and vardenafil: results from the erectile dysfunction observational study (EDOS). Eur. Urol. 51, 541–550 (2007).
Sun, P., Seftel, A., Swindle, R., Ye, W. & Pohl, G. The costs of caring for erectile dysfunction in a managed care setting: evidence from a large national claims database. J. Urol. 174, 1948–1952 (2005).
Burnett, A. L., Allaf, M. E. & Bivalacqua, T. J. Erythropoietin promotes erection recovery after nerve-sparing radical retropubic prostatectomy: a retrospective analysis. J. Sex. Med. 5, 2392–2398 (2008).
Hatzimouratidis, K. & Hatzichristou, D. G. Looking to the future for erectile dysfunction therapies. Drugs 68, 231–250 (2008).
van der Ploeg, L. H. et al. A role for the melanocortin 4 receptor in sexual function. Proc. Natl Acad. Sci. USA 99, 11381–11386 (2002).
Diamond, L. E., Earle, D. C., Rosen, R. C., Willett, M. S. & Molinoff, P. B. Double-blind, placebo controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int. J. Impot. Res. 16, 51–59 (2004).
Martinez, R., Puigvert, A., Pomerol, J. M. & Rodriguez-Villalba, R. Clinical experience with apomorphine hydrochloride: the first 107 patients. J. Urol. 170, 2352–2355 (2003).
Song, Y. & Rajasekaran, M. Effect of excitatory amino acid receptor agonists on penile erection after administration into the CA3 hippocampal region in the rat. Urology 64, 1250–1254 (2004).
Bivalacqua, T. J. et al. RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: a mechanism for diabetes-associated erectile dysfunction. Proc. Natl Acad. Sci. USA 101, 9121–9126 (2004).
Chitaley, K., Webb, R. C. & Mills, T. M. Rho-kinase as a potential target for the treatment of erectile dysfunction. Drug News Perspect. 14, 601–606 (2001).
Andersson, K. E. Pharmacology of penile erection. Pharmacol. Rev. 53, 417–450 (2001).
Succu, S. et al. Oxytocin induces penile erection when injected into the ventral tegmental area of male rats: role of nitric oxide and cyclic GMP. Eur. J. Neurosci. 28, 813–821 (2008).
Kershen, R. T., Yoo, J. J., Moreland, R. B., Krane, R. J. & Atala, A. Reconstitution of human corpus cavernosum smooth muscle in vitro and in vivo. Tissue Eng. 8, 515–524 (2002).
Loeb, S., Roehl, K. A., Helfand, B. T. & Catalona, W. J. Complications of open radical retropubic prostatectomy in potential candidates for active monitoring. Urology 72, 887–891 (2008).
Bianco, F. J. Jr, Scardino, P. T. & Eastham, J. A. Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function (“trifecta”). Urology 66, 83–94 (2005).
Su, L. M., Link, R. E., Bhayani, S. B., Sullivan, W. & Pavlovich, C. P. Nerve-sparing laparoscopic radical prostatectomy: replicating the open surgical technique. Urology 64, 123–127 (2004).
Patel, V. R., Thaly, R. & Shah, K. Robotic radical prostatectomy: outcomes of 500 cases. BJU Int. 99, 1109–1112 (2007).
Acknowledgements
Désirée Lie, University of California, Irvine, CA, is the author of and is solely responsible for the content of the learning objectives, questions and answers of the MedscapeCME-accredited continuing medical education activity associated with this article.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Magheli, A., Burnett, A. Erectile dysfunction following prostatectomy: prevention and treatment. Nat Rev Urol 6, 415–427 (2009). https://doi.org/10.1038/nrurol.2009.126
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2009.126
This article is cited by
-
Erection rehabilitation following prostatectomy — current strategies and future directions
Nature Reviews Urology (2016)
-
Erectile function following brachytherapy, external beam radiotherapy, or radical prostatectomy in prostate cancer patients
Strahlentherapie und Onkologie (2016)
-
Adipose Tissue-Derived Stem Cells for the Treatment of Erectile Dysfunction
Current Urology Reports (2016)
-
Therapeutic potential of human umbilical cord blood mesenchymal stem cells on erectile function in rats with cavernous nerve injury
Biotechnology Letters (2015)
-
Improving sexual health in men with prostate cancer: randomised controlled trial of exercise and psychosexual therapies
BMC Cancer (2014)